Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Cellectis

Tracked across 3 events · 19 articles · First seen Apr 10, 2026 · Last active Jul 02, 2026

Sentiment
48
Attention
4
Events
3
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 75
Regulatory
Impact: Cellectis received Regenerative Medicine Advanced Therapy (RMAT) designation from the United States — Food and Drug Administration>>> for its product candidate, lasme-cel, which is a significant positive development for the company's clinical program and market position.
Jun 09, 2026 · 6 articles
4 70
Tech
Impact: Cellectis presented positive Phase 1 data for its CAR-T therapies, lasme-cel and eti-cel, which could lead to accelerated development and increased investor confidence.
Jun 11, 2026 · 7 articles
1 0
Business
Impact: Cellectis is the company providing monthly updates on its total number of shares and voting rights.
Jun 03, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Cellectis live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.